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H E A L T H  A N D  M E D I C I N E
Response to Comment on “A commensal strain of 
Staphylococcus epidermidis protects against skin 
neoplasia” by Nakatsuji et al.
Teruaki Nakatsuji1, William Fenical2, Richard L. Gallo1*
Kozmin et al. contend that observations previously reported regarding the antimicrobial and antitumor activities 
of 6-N-hydroxy aminopurine (6-HAP) were incorrect. Their conclusions rely on poorly characterized reagents and 
focus strictly on in vitro techniques without validation in relevant mammalian model systems. We are pleased to be 
able to illuminate the weaknesses in their technical comment. The totality of current results continues to support 
our original conclusion that a strain of the common human commensal skin bacterium, Staphylococcus epidermidis, 
produces 6-HAP that can inhibit tumor growth.
THE REAGENT USED BY KOZMIN ET AL. WAS NOT 6-HAP
In their technical comment (1), the authors report that they used 
a commercially available form of 6-N-hydroxy aminopurine (6-HAP) 
purchased from MP Biomedicals (Chemical Abstracts Service 
no. 5667-20-9). We will refer to this chemical as 6-HAP-MPB. The 
authors used this reagent to test in vitro mutagenic activity. To 
investigate their discrepancies with our findings, we purchased 
6-HAP-MPB from this supplier and observed that the reagent upon 
which they based their conclusions is not 6-HAP. That 6-HAP-
MPB is not 6-N-hydroxy aminopurine is obvious from the package 
label that states this commercial product has a molecular weight 
of 1151.13 (Fig. 1). This does not correspond to the mass of 6-HAP 
(theoretical mass, 151.0489). To determine whether this was only a 
typographical error, we next applied high-resolution electrospray 
ionization time of flight mass spectrometry (HR-ESI-TOF-MS) 
analysis to the commercial lot of 6-HAP-MPB (Fig. 2). Three major 
peaks [mass/charge ratio (m/z) = 257.2476, 285.2789, and 445.3736] 
were detected by positive mode that correspond to C16H33O2, 
C18H37O2, and C21H46N7O3, respectively. No mass corresponding 
to 6-HAP was detected in this lot of 6-HAP-MPB. Furthermore, 
since authentic 6-HAP has potent antimicrobial activity against 
group A Streptococcus, we also tested the antimicrobial function of 
the commercial compound used by Kozmin et al. 6-HAP-MPB 
did not have antimicrobial activity (Fig. 3). We therefore suggest 
that their conclusions are based on an unknown substance and 
not 6-HAP. Furthermore, the identification error made by Kozmin 
et al. is not without precedent. Synthetic products assumed to be 
6-HAP have been studied in previous papers (2, 3). Mutagenic 
activity was reported for a compound assumed to be 6-HAP 
without characterization of the chemical structure of the reagent 
used for testing (4, 5). Kozmin et al. repeated this error and 
also based their conclusions on an uncharacterized commercial 
product.
Validation of reagents is essential for all experimentation, but par-
ticularly necessary in this case. In our report, we identified 6-HAP 
from an unbiased screen of bacterial products without prejudice. The 
chemical structure of the active molecule produced from Staphylococcus 
epidermidis MO34 was solved by high- performance liquid chroma-
tography, high-resolution ESI-MS, isotope incorporation assay, 
1H nuclear magnetic resonance, 2D-gHMBC (two-dimensional 
gradient- selected heteronuclear multiple-bond correlation) spectral 
data, and fragmentation profile on ESI-MS. This analysis was followed by 
repeat chemical synthesis and validation of the synthetic molecule 
[see original figures from our manuscript (6): Fig. 1D and figs. S1 to S5]. 
Given the results from these multiple independent approaches, we 
confirmed that we were working with 6-HAP. No such characteriza-
tion was done by Kozmin et al., and therefore, the conclusions they 
reached are not valid.
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Fig. 1. Molecular weight of 6-HAP-MPB on the package label does not correspond to that of 6-HAP.  (Photo credit: Teru Nakatsuji, University of California, San Diego.)
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MUTAGENESIS ASSAYS USED BY THE AUTHORS WERE NOT 
PHYSIOLOGICALLY RELEVANT
To support their conclusions with the unknown chemical in 6-HAP-
MPB, they also performed some experiments using a crude synthetic 
product and an extract of the culture supernatant of S. epidermidis 
MO34. These were given to them with information that these reagents 
required further characterization and purification. These crude pro-
ducts are unstable. 6-HAP is spontaneously deoxidized within 24 hours 
in aqueous solutions at normal atmosphere and room temperature. 
This results in a molecule with a chemical formula of C5H5N5, which 
does not have biological activity (Fig. 4). Without validation of their 
working reagents, their conclusions must be considered unreliable.
Even if Kozmin et al. had used authentic 6-HAP, the assays they 
used were not physiologically relevant. To measure mutagenic ac-
tivity by Ames test or a mouse lymphoma assay, target cells must be in-
cubated with a mutagen for 4 and 7 days, respectively. This is much longer 
than the term of stability of 6-HAP in solution. In addition, as shown 
in our original manuscript, mitochondorial amidoxyme–reducing 
components in normal human cells rescue cells from the anti metabolite 
activity of 6-HAP. As a consequence of this rapid inactivation reaction, 
Fig. 2. 6-HAP-MPB does not contain a chemical that is identical to 6-HAP. (A) 6-HAP-MPB was dissolved in 99% acetonitrile/1% TFA (trifluoroacetic acid) and subjected 
to high-resolution ESI-TOF-MS. Peaks were scanned between m/z 100 and 1250 in positive ion mode. (B) Estimated chemical composition of three major peaks detected 
in 6-HAP-MPB. None of them correspond to that of 6-HAP (theoretical mass, 151.0489).
Fig. 3. 6-HAP has antimicrobial activity, but 6-HAP-MPB does not. Antimicrobial 
activity of indicated concentration of 6-HAP or 6-HAP-MPB was measured against 
group A Streptococcus (NZ131) with a radial diffusion assay. Black circle of zone of 
growth inhibition represents antimicrobial activity of 6-HAP (arrows). The method 
of this assay has been provided in our original manuscript.
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6-HAP does not show systemic toxicity in mice and does not inhib-
it the growth of normal human keratinocytes.
To avoid the natural instability of 6-HAP, Kozmin et al. con-
ducted their mutagenic assays using a moaA bacterial mutant, 
which cannot detoxify 6-HAP to the canonical nucleobase. They 
detected mutagenic activity only in the moaA mutant but not in 
wild-type bacteria. This illuminates another example of why the 
conclusions in their commentary are not physiologically relevant. 
The authors also argue that 0.5 and 1 g/ml at which we tested for 
mutagenic activity by Ames test was too high; however, Escherichia coli 
TA100 used for the Ames test is not killed at these concentrations 
by 6-HAP. We have also shown that this concentration is relevant 
since the final yield of purified 6-HAP is 7 mg from 6.4 liters of 
conditioned media of S. epidermidis MO34. Therefore, the concen-
tration we tested was comparable to the concentrations which bacteria 
can produce in vivo. The authors’ claim of a false-negative Ames test 
is without data to support it.
The authors also invert their argument to claim that the concen-
tration of 6-HAP we used in our mouse lymphoma assay (0.25 g/ml) 
was too low. They suggest use of at least 5 g/ml of 6-HAP to test 
mutagenic activity in this assay. However, they ignored data showing 
that native 6-HAP at >0.2 g/ml inhibits BrdU (bromo deoxyuridine) 
incorporation in the mouse lymphoma cell line F5178 (parental cell 
line of T5178Ytk+/− used for mouse lymphoma assay). Thus, we tested 
the mutagenic activity on mouse lymphoma at the highest concentra-
tion that did not inhibit cell proliferation. These toxic effects of 6-HAP 
on cells that lack mitochondorial amidoxyme–reducing components 
explain the antitumor effects of 6-HAP. It cannot be a mutagen in 
transformed cells because of its toxicity and cannot be a mutagen in 
normal cells because of its instability.
MOUSE ASSAYS SHOW 6-HAP INHIBITS TUMOR GROWTH
Last, but perhaps most importantly, the authors do not mention 
data from our publication that validated conclusions by using two 
different mouse models. We demonstrated that repeated injections 
with validated and purified 6-HAP inhibited growth of a melanoma 
cell line growing in mice. We also showed that applying S. epidermidis 
MO34 that produces 6-HAP, but not a control S. epidermidis strain, 
suppressed new tumor formation in a two-stage carcinogenesis model. 
Mutagenesis was not observed in mice injected with 6-HAP or colo-
nized by an MO34 strain for 12 weeks. These observations in mice 
were also supported by metagenomic evidence that S. epidermidis 
strains with the capacity to produce 6-HAP are common in healthy 
human populations. Together, these data in mice and observations 
in humans make it highly improbable that 6-HAP promotes muta-
genesis in physiological settings.
CONCLUSIONS
We disagree with the statements by Kozmin et al. that 6-HAP is 
mutagenic. In direct contrast to the comments of these authors, 
our results were based on an unbiased approach followed by care-
ful chemical characterization, physiologically relevant bioassays, 
mouse experiments, and human observations. These results all 
support the prior conclusion that 6-HAP is protective against 
tumor development. We encourage further careful work to address 
this issue. Although either conclusion is highly relevant and high-
lights the importance of the microbiome to human health, a care-
ful evaluation of currently available data suggests that 6-HAP is a 
beneficial product of the skin microbiome and not a mutagenic 
chemical.
Fig. 4. 6-HAP can be spontaneously deoxidized in solution within 24 hours. (A and B) Native 6-HAP was dissolved in heated H2O (60°C) at 0.1 mg/ml and incubated 
at room temperature for 24 hours. Degradation of 6-HAP was characterized by low-resolution ESI-TOF-MS (A), followed by the high-resolution mode (B). All 6-HAP was 
degraded after a 24-hour incubation. (C) Estimated chemical composition of two major peaks detected in (B).
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